Company: LENZ
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001815776-25-000032
Chunk: 288

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 288
---
Item 1. Financial Statements.

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for shares and par value)

March 31, 2025December 31, 2024(unaudited)AssetsCurrent assets:Cash and cash equivalents$23,042 $20,158 Marketable securities170,934 188,872 Prepaid expenses and other current assets3,769 2,773 Restricted cash114 114 Total current assets197,859 211,917 Property and equipment, net926 651 Operating lease right-of-use asset1,069 1,338 Other assets1,398 1,398 Total assets$201,252 $215,304 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$3,661 $4,257 Accrued liabilities4,908 6,149 Total current liabilities8,569 10,406 Operating lease liability, net673 814 Total liabilities9,242 11,220 Commitments and contingencies (Note 6)Stockholders' equity:Common stock, par value of $0.00001 per share; 300,000,000 shares authorized; 27,543,120 and 27,531,490 shares issued at March 31, 2025 and December 31, 2024, respectively; and 27,535,663 and 27,518,439 shares outstanding at March 31, 2025 and December 31, 2024, respectively1 1 Additional paid-in capital351,519 348,901 Accumulated deficit(159,633)(145,014)Accumulated other comprehensive income123 196 Total stockholders’ equity192,010 204,084 Total liabilities and stockholders’ equity$201,252 $215,304 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

Table of Contents

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

(unaudited)

Three Months Ended March 31,20252024Operating expenses:Research and development$5,818 $10,537 Selling, general and administrative11,113 5,551 Total operating expenses16